Abstract:Therapeutic Advances in Drug Safety, Volume 15, Issue , January-December 2024. Background:With the increasing prescription of reslizumab for severe asthma with an eosinophilic phenotype, a real-world pharmacovigilance analysis of reslizumab is urgently required to detect potential unreported adverse events (AEs) in clinical practice.Objectives:We aimed to provide a comprehensive evaluation of reslizumab-related AEs in the real world.Design:Disproportionality analysis based on the FDA Adverse Event Reporting System (FAERS) database.Methods:Reslizumab-related AEs between the second quarter of 2016 and the fourth quarter of 2022 from the FAERS database were obtained. A disproportionality analysis was performed to evaluate the safety profile of reslizumab using the reporting odds ratio.Results:A total of 10,450,353 reports were collected from the FAERS database. Of the 403 reslizumab-related AEs, 42 distinct AEs were identified with positive signals. The most common AEs including dyspnea and oropharyngeal pain were identified, consistent with the instruction and clinical studies. Unexpected AEs of disproportionality such as bronchospasm and chest pain were also observed. Drug ineffective was identified as a noteworthy concern that accounted for 13.90% (56/403) of the overall reslizumab-related reports.Conclusion:While reslizumab offered a promising treatment option for severe eosinophilic asthma, more attention should be paid to the common AEs and new unexpected AEs. Based on the current findings of signal detection, further prospective studies are needed for the next signal validation and confirmation.Plain language summaryA pharmacovigilance analysis of reslizumabBackground:Reslizumab is a humanized monoclonal antibody that has been approved by the United States Food and Drug Administration (FDA) since 2016 for the add-on maintenance treatment of eosinophilic severe asthma. A safety profile identifies common and new unexpected adverse events (AEs) based on the data from clinical studies and post-marketing surveillance to guide informed decisions. So far, the safety profile of reslizumab has been unclear.Methods:In this study, we aimed to provide a comprehensive evaluation of reslizumab-related AEs in the real world based on the FDA Adverse Event Reporting System (FAERS) database. We analyzed the collected data using the reporting odds ratio (ROR).Results:Our study identified the most common AEs such as dyspnea and oropharyngeal pain, which were consistent with the instruction and clinical studies. We also observed unexpected AEs of disproportionality including bronchospasm and chest pain. Moreover, we identified drug ineffective as a noteworthy concern that should be addressed in future research.Conclusion:We identified new unexpected AEs in addition to the common AEs indicated in the instructions. We also emphasized the importance of correct administration protocols for reslizumab. Based on the current findings of signal detection, further prospective studies are needed for the next signal validation and confirmation.

Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)

Central Serous Chorioretinopathy Secondary to Drugs: a Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).

A Real-World Disproportionality Analysis of FDA Adverse Event Reporting System (FAERS) Events for Baricitinib.

Ocular adverse events associated with GLP-1 receptor agonists: a real-world study based on the FAERS database and network pharmacology

Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment

Disproportionality analysis of reslizumab based on the FDA Adverse Event Reporting System

Gains in the current understanding of managing neovascular AMD with brolucizumab

Efficacy, Safety, and Durability of Brolucizumab: An 8-Month Post-Marketing Surveillance Analysis

Manifestations of intraocular inflammation over time in patients on brolucizumab for neovascular AMD

Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map

A real-world pharmacovigilance analysis of the FDA adverse event reporting system events for polatuzumab vedotin

Occlusive retinal vasculitis and scleritis following brolucizumab treatment: A case report

The real-world analysis of adverse events with teduglutide: a pharmacovigilance study based on the FAERS database

A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system

Side Effects of Brolucizumab

Data mining and analysis for emicizumab adverse event signals based on the Food and Drug Administration Adverse Event Reporting System database

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for denosumab

Real-World Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System Database for Asciminib

A real-world disproportionality analysis of cyclosporine from the FDA Adverse Event Reporting System (FAERS) database

Adverse Event Assessment of Upadacitinib: A Pharmacovigilance Study Based on the FAERS Database

Safety assessment of dapagliflozin: Real-world adverse event analysis based on the FAERS database from 2012 to 2023